Freddy T. Nguyen, MD, PhD, CEO and Co-Founder of Nine Diagnostics, joined the Health and Explainable AI (HexAI) Podcast for an episode titled “Innovating Precision Medicine with Dr. Freddy Nguyen,” released May 14, 2026. The podcast is a collaborative initiative between the Health and Explainable AI (HexAI) Research Lab in the Department of Health Information Management at the University of Pittsburgh School of Health and Rehabilitation Sciences, and the Computational Pathology and AI Center of Excellence (CPACE) at the University of Pittsburgh School of Medicine.
The conversation covers Nguyen’s path from clinical training and measurement science research at MIT to co-founding Nine Diagnostics, and the entrepreneurship pathway behind building a diagnostics company around a novel platform technology. Nguyen discusses how Nine Diagnostics’ AI-enabled multi-omic nanosensor platform generates molecular fingerprints that combine proteomic, metabolomic, and lipidomic signals, applying machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter.
The episode examines how molecular fingerprinting and multimodal AI are shifting oncology from static genomic snapshots, a single measurement taken at one point in time, toward real-time functional precision medicine capable of tracking how a patient’s disease and treatment response evolve. This distinction is central to Nine Diagnostics’ focus on on-treatment monitoring: using the platform to help determine whether a therapy is working while treatment is underway, rather than relying solely on pre-treatment genomic profiling.
Nine Diagnostics’ AI-enabled nanosensor platform is built on published peer-reviewed validation. In Nature Nanotechnology (Goerzen et al., 2026), the platform demonstrated 98% accuracy in brain tumor detection and 71% accuracy in tumor type identification across 739 patient samples at Memorial Sloan Kettering Cancer Center, Northwestern University, and NYU, representing the first multi-site clinical validation of the approach. In Nature Biomedical Engineering (Kim et al., 2022), the platform demonstrated 87% sensitivity and 98% specificity for high-grade serous ovarian cancer detection across 269 patient samples.
This work forms the scientific foundation of Nine Diagnostics, co-founded in 2024 by Freddy T. Nguyen, MD, PhD, Daniel A. Heller, PhD, and Mijin Kim, PhD. Listen to the full episode on Spotify.
About Nine Diagnostics
Nine Diagnostics is an AI-enabled multi-omic nanosensor company advancing precision medicine. The platform simultaneously captures proteomic, metabolomic, and lipidomic signals alongside patient clinical context to generate a multi-omic fingerprint, using machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter. This enables pre-treatment patient stratification, on-treatment response monitoring, and post-treatment minimal residual disease detection. Founded by Freddy T. Nguyen, MD, PhD (CEO), Daniel A. Heller, PhD (CSO), and Mijin Kim, PhD (Scientific Advisor), Nine Diagnostics is based in Cambridge, Massachusetts.